Cutter Capital Management, L.P. 13F annual report

Cutter Capital Management, L.P. is an investment fund managing more than $519 billion ran by Kerry Kourepenos. There are currently 25 companies in Mrs. Kourepenos’s portfolio. The largest investments include Bristol-Myers Squibb Co and Gilead Sciences, together worth $87.4 billion.

$519 billion Assets Under Management (AUM)

As of 30th July 2024, Cutter Capital Management, L.P.’s top holding is 893,800 shares of Bristol-Myers Squibb Co currently worth over $48.5 billion and making up 9.3% of the portfolio value. Relative to the number of outstanding shares of Bristol-Myers Squibb Co, Cutter Capital Management, L.P. owns more than approximately 0.1% of the company. In addition, the fund holds 530,872 shares of Gilead Sciences worth $38.9 billion, whose value fell 3.7% in the past six months. The third-largest holding is Teva Pharmaceutical Inds Ltd worth $32 billion and the next is Regeneron Pharmaceuticals worth $31.5 billion, with 32,720 shares owned.

Currently, Cutter Capital Management, L.P.'s portfolio is worth at least $519 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Cutter Capital Management, L.P.

The Cutter Capital Management, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Kerry Kourepenos serves as the COO at Cutter Capital Management, L.P..

Recent trades

In the most recent 13F filing, Cutter Capital Management, L.P. revealed that it had opened a new position in Gilead Sciences and bought 530,872 shares worth $38.9 billion. This means they effectively own approximately 0.1% of the company. Gilead Sciences makes up 9.4% of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.

The investment fund also strengthened its position in Bristol-Myers Squibb Co by buying 753,800 additional shares. This makes their stake in Bristol-Myers Squibb Co total 893,800 shares worth $48.5 billion. Bristol-Myers Squibb Co dropped approximately 0.1% in the past year.

On the other hand, there are companies that Cutter Capital Management, L.P. is getting rid of from its portfolio. Cutter Capital Management, L.P. closed its position in AMGEN on 6th August 2024. It sold the previously owned 57,381 shares for $16.5 billion.

One of the average hedge funds

The two most similar investment funds to Cutter Capital Management, L.P. are Crane Advisory and Crow's Nest L.P.. They manage $519 billion and $519 billion respectively.

Kerry Kourepenos investment strategy

Cutter Capital Management, L.P.’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 80.2% of the total portfolio value. The fund focuses on investments in the United States as 68.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 28% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $25.9 billion.

The complete list of Cutter Capital Management, L.P. trades based on 13F SEC filings

These positions were updated on August 6th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Bristol-Myers Squibb Co.	538.43% 893,800	$48,470,774,000	9.34%
Gilead Sciences, Inc.	Opened 530,872	$38,886,374,000	7.50%
Teva Pharmaceutical Inds Ltd	113.95% 2,271,420	$32,049,736,000	6.18%
Regeneron Pharmaceuticals, Inc.	Opened 32,720	$31,492,672,000	6.07%
Biomarin Pharmaceutical Inc.	169.43% 350,000	$30,569,000,000	5.89%
Ionis Pharmaceuticals Inc	Opened 578,732	$25,088,032,000	4.84%
Royalty Pharma plc	122.45% 823,080	$24,996,940,000	4.82%
Sarepta Therapeutics Inc	Opened 188,758	$24,436,610,000	4.71%
Acadia Pharmaceuticals Inc	297.86% 1,316,818	$24,347,964,000	4.69%
Biogen Inc	Opened 104,000	$22,425,520,000	4.32%
Biocryst Pharmaceuticals Inc.	176.70% 4,210,918	$21,391,464,000	4.12%
Halozyme Therapeutics Inc.	112.14% 510,098	$20,750,786,000	4.00%
Perrigo Co Plc	147.78% 644,228	$20,737,700,000	4.00%
Exelixis Inc	72.51% 797,524	$18,925,244,000	3.65%
Avadel Pharmaceuticals plc	Opened 1,083,852	$18,306,260,000	3.53%
Eli Lilly & Co	Opened 22,080	$17,177,356,000	3.31%
Agios Pharmaceuticals Inc	Opened 577,160	$16,876,158,000	3.25%
AMGEN Inc.	Closed 57,381	$16,526,876,000
CRISPR Therapeutics AG	123.60% 240,370	$16,383,620,000	3.16%
Arcellx Inc	Opened 214,000	$14,883,700,000	2.87%
Merck & Co Inc	Closed 136,098	$14,837,404,000
Amicus Therapeutics Inc	Closed 947,418	$13,443,861,000
Insmed Inc	9.96% 454,674	$12,335,306,000	2.38%
Roivant Sciences Ltd	Closed 1,000,000	$11,230,000,000
Viridian Therapeutics Inc	81.10% 557,276	$9,757,902,000	1.88%
Legend Biotech Corp	Opened 159,660	$8,955,330,000	1.73%
Kyverna Therapeutics Inc	Opened 333,028	$8,272,416,000	1.59%
Pfizer Inc.	Closed 265,000	$7,629,350,000
Apellis Pharmaceuticals Inc	Closed 108,000	$6,464,880,000
Pliant Therapeutics, Inc.	Opened 388,238	$5,784,746,000	1.12%
Iovance Biotherapeutics Inc	Closed 677,350	$5,506,856,000
Cabaletta Bio Inc	37.36% 315,928	$5,389,732,000	1.04%
Prestige Consmr Healthcare I	Closed 85,000	$5,203,700,000
BridgeBio Pharma Inc	Closed 103,324	$4,171,190,000
Arcus Biosciences Inc	Closed 192,667	$3,679,940,000
No transactions found
Showing first 500 out of 35 holdings